Synchrony between Ovarian Function & Sleep in Polycystic Ovary Syndrome Patients


Polycystic ovary syndrome (PCOS) is a complex, multifaceted, heterogeneous disorder, affecting 4% to 18% of reproductive-aged women and is associated with reproductive, metabolic and psychological dysfunction. In this study we determined the relationship between the time to sleep and serum levels of neurohormones in polycystic ovary syndrome (PCOS). Totally 77 PCO patients(case group) and 97 non-PCOS infertile women (control subjects) participated in this study between February 2012 and February 2013. A PSQI sleep questionnaire was completed by each patient in both groups. PSQI sleep questionnaire score and serum concentration of adrenaline, noradrenaline, melatonin, β-endorphin, cortisol and progesterone were compared in two groups. The results of the study indicate that serum levels of melatonin and β-endorphin were lower in women with PCOS. Serum level of stress hormones, adrenaline and noradrenaline were significantly correlated with patients’ sleep time in study group. Serum level of adrenaline in control group was significantly lower in women who wake up earlier in the morning. All hormones except for cortisol had no significant correlation with PSQI global score in both groups and also the people who sleep less than 8 hours had lower cortisol level. These data showed that changes in cortisol in PCO women were due to damage of disturbed sleep at night. Our preliminary work provided this study with new insight into the interactions between sleep-wake cycles in PCO women with specific sleep patterns.

Share and Cite:

Zangeneh, F. , Naghizadeh, M. , Abdollahi, A. and Bagheri, M. (2014) Synchrony between Ovarian Function & Sleep in Polycystic Ovary Syndrome Patients. Open Journal of Obstetrics and Gynecology, 4, 725-731. doi: 10.4236/ojog.2014.412101.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Norman, R.J., Dewailly, D., Legro, R.S. and Hickey, T.E. (2007) Polycystic Ovary Syndrome. The Lancet, 370, 685-697.
[2] Badawy, A. and Elnashar, A. (2011) Treatment Options for Polycystic Ovary Syndrome. International Journal of Women’s Health, 3, 25-35.
[3] Yen, S.S.C. (1999) The Human Menstrual Cycle: Neuroendocrine Regulation. In: Yen, S.S.C., Jaffe, R.B. and Barbieri, R.L., Eds., Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, W.B. Saunders Co., Philadelphia, 191-217.
[4] Baker, F.C. and Driver, H.S. (2007) Circadian Rhythms Sleep and the Menstrual Cycle. Sleep Medicine, 8, 613-622.
[5] Lansdown, A. and Rees, D.A. (2012) The Sympathetic Nervous System in Polycystic Ovary Syndrome: A Novel Therapeutic Target? Clinical Endocrinology (Oxford), 77, 791-801.
[6] Borbely, A.A. (1982) A Two Process Model of Sleep Regulation. Human Neurobiology, 1, 195-204.
[7] Carskadon, M.A., Acebo, C. and Jenni, O.G. (2004) Regulation of Adolescent Sleep: Implications for Behavior. Annals of the New York Academy of Sciences, 1021, 276-291.
[8] Karatsoreos, I.N., Bhagat, S., Bloss, E.B., Morrison, J.H. and McEwen, B.S. (2011) Disruption of Circadian Clocks Has Ramifications for Metabolism, Brain, and Behavior. Proceedings of the National Academy of Sciences of the United States of America, 108, 1657-1662.
[9] Zangeneh, F.Z., Naghizade, M.M., Abedinia, N., Haghollahi, F. and Hezarehei, D. (2012) Psychological Signs in Patients with Polycystic Ovary Syndrome. Journal of Family and Reproductive Health, 6, 145-151.
[10] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS). Human Reproduction, 19, 41-47.
[11] Born, J., Hansen, K., Marshall, L., Molle, M. and Fehm, H.L. (1999) Timing the End of Nocturnal Sleep. Nature, 397, 29-30.
[12] Wüst, S., Wolf, J., Hellhammer, D.H., Federenko, I., Schommer, N. and Kirschbaum, C. (2000) The Cortisol Awakening Response—Normal Values and Confounds. Noise Health, 2, 79-88.
[13] Fries, E., Dettenborn, L. and Kirschbaum, C. (2009) The Cortisol Awakening Response (CAR): Facts and Future Directions. International Journal of Psychophysiology, 72, 67-73.
[14] Schmidt-Reinwald, A., Pruessner, J.C., Hellhammer, D.H., Federenko, I., Rohleder, N., Schürmeyer, T.H. and Kirschbaum, C. (1999) The Cortisol Response to Awakening in Relation to Different Challenge Tests and a 12-Hour Cortisol Rhythm. Life Sciences, 64, 1653-1660.
[15] Wolf, O.T., Fujiwara, E., Luwinski, G., Kirschbaum, C. and Markowitsch, H.J. (2005) No Morning Cortisol Response in Patients with Severe Global Amnesia. Psychoneuroendocrinology, 30, 101-105.
[16] Kudielka, B.M. and Kirschbaum, C. (2003) Awakening Cortisol Responses Are Influenced by Health Status and Awakening Time but Not by Menstrual Cycle Phase. Psychoneuroendocrinology, 28, 35-47.
[17] Schlotz, W., Hellhammer, J., Schulz, P. and Stone, A.A. (2004) Perceived Work Overload and Chronic Worrying Predict Weekend-Weekday Differences in the Cortisol Awakening Response. Psychosomatic Medicine, 66, 207-214.
[18] Prelevic, G.M., Würzburger, M.I. and Balint-Peric, L. (1993) 24-Hour Serum Cortisol Profiles in Women with Polycystic Ovary Syndrome. Gynecological Endocrinology, 7, 179-184.
[19] Pasquali, R. and Gambineri, A. (2012) Cortisol and the Polycystic Ovary Syndrome. Expert Review of Endocrinology & Metabolism, 7, 555-566.
[20] Milutinovic, D.V., Macut, D., Bozic, I., Nestorov, J., Damjanovic, S. and Matic, G. (2011) Hypothalamic-Pituitary-Adrenocortical Axis Hypersensitivity and Glucocorticoid Receptor Expression and Function in Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology & Diabetes, 119, 636-643.
[21] Hobson, J.A. and Pace-Schott, E.F. (2002) The Cognitive Neuroscience of Sleep: Neuronal Systems, Consciousness and Learning. Nature Reviews Neuroscience, 3, 679-693.
[22] Berridge, C.W., Isaac, S.O. and Espana, R.A. (2003) Additive Wake-Promoting Actions of Medial Basal Forebrain Noradrenergic Alpha1- and Beta-Receptor Stimulation. Behavioral Neuroscience, 117, 350-359.
[23] Kawabe, T., Chitravanshi, V.C., Kawabe, K. and Sapru, H.N. (2006) Cardiovascular Effects of Adrenocorticotropin Microinjections into the Rostral Ventrolateral Medullary Pressor Area of the Rat. Brain Research, 1102, 117-126.
[24] Reyes, B.A.S., Glaser, J.D., Magtoto, R. and Van Bockstaele, E.J. (2006) Pro-Opiomelanocortin Colocalizes with Corticotropin-Releasing Factor in Axon Terminals of the Noradrenergic Nucleus Locus Coeruleus. European Journal of Neuroscience, 23, 2067-2077.
[25] Mansour, A., Fox, C.A., Akil, H. and Watson, S.J. (1995) Opioid-Receptor mRNA Expression in the Rat CNS: Anatomical and Functional Implications. Trends in Neurosciences, 18, 22-29.
[26] Zangeneh, F.Z., Mohammadi, A., Ejtemaeimehr, S.H., Naghizadeh, M.M. and Aminee, F. (2011) The Role of Opioid System and Its Interaction with Sympathetic Nervous System in the Processing of Polycystic Ovary Syndrome Modeling in Rat. Archives of Gynecology and Obstetrics, 283, 885-892.
[27] Genazzani, A.R., Genazzani, A.D., Volpogni, C., Pianazzi, F., Li, G.A., Surico, N. and Petraglia, F. (1993) Opioid Control of Gonadotrophin Secretion in Humans. Human Reproduction, 8, 151-153.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.